National Medical Products Administration

Name

National Medical Products Administration

Legal name

National Medical Products Administration

Website

https://english.nmpa.gov.cn

Company type

Private

Founded year

1950

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory Services

NAICS

Regulation, Licensing, and Inspection of Miscellaneous Commercial Sectors (92615)

akta.pro primary industry

Drug Regulators (Human Pharmaceuticals) (HLAJADAA)

akta.pro secondary industries

Medical Device Regulators (HLAJADAC), Manufacturing Quality, GMP Inspections & Compliance (HLAJADAG), Regulatory Affairs, Labeling & Advertising/Promotion Compliance (HLAJADAI), Regulatory Compliance, Licensing & Enforcement (Public Health) (HLAJAMAE)

Keywords

• Drug regulatory approval
• Medical device registration
• Cosmetics filing
• Pharmaceutical GMP inspection
• Export certification

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels3 records

Core offering

National Medical Products Administration regulates and supervises drugs, medical devices, and cosmetics in China through marketing authorizations, registration reviews, GMP inspections, export certification, and pharmacopoeia standards. It issues binding regulatory frameworks, maintains public databases of approved products, and operates affiliated technical centers that conduct scientific reviews, inspections, and laboratory testing.

Product overview

National Medical Products Administration (NMPA) is China's primary regulatory agency for drugs, medical devices, and cosmetics. The organization provides a portfolio of regulatory services including the NMPA Database for public access to approvals and registrations, the NMPA Newsletter for periodic updates, the Worldwide Pharmacopoeia for quality standards, and Policies Interpretation for regulatory guidance. Key affiliated institutions include the Center for Drug Evaluation, Center for Medical Device Evaluation, Center for Food and Drug Inspection, National Institutes for Food and Drug Control, and Chinese Pharmacopoeia Commission. Recent initiatives include the Opinions on Integrated Development of AI and Drug Regulation, the Cosmetics Electronic Label System using QR codes, and AI-enabled medical devices such as the CT Angiography Image-aided Detection Software and Innovative Neurosurgical Planning Software. Regulatory frameworks include the revised Good Manufacturing Practice for Medical Devices and Administrative Provisions on Export Certification for Pharmaceutical Products.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Marketing Authorization Service Statutory review and approval of drug registration applications for innovative drugs, generics, imported pharmaceuticals, and traditional Chinese medicines marketed in China. Handles Class 1 innovative drug approvals, priority review and approval procedures, and technical review through the Center for Drug Evaluation.
• Medical Device Registration Service Technical review and approval of medical device registration applications, including innovative medical devices, through the Center for Medical Device Evaluation. Issues approvals that contribute to milestones such as the 300th innovative medical device approval.
• Cosmetics Registration and Filing Service Registration and filing services for domestic and foreign cosmetics manufacturers and importers, including requirements for electronic label implementation via QR code for consumer-facing label information access.
• Pharmaceutical Export Certificate Service Administrative Provisions on Inspection and Export Certificate for Pharmaceutical Products Exported by Pharmaceutical Manufacturers ([2025] No. 113), effective January 1, 2026, providing inspection and certification for pharmaceutical products manufactured in China for export markets, with WHO Certification Scheme template alignment.
• GMP Compliance Inspection Service Good Manufacturing Practice inspections for drug and medical device manufacturing facilities, with provisions aligned with PIC/S requirements and mutual recognition with EDQM GMP inspections for active substances exported to the EU.
• Good Manufacturing Practice for Medical Devices (Revised GMP) Revised quality management system requirements for medical device manufacturing, consisting of 15 chapters and 132 articles, with new chapters on quality assurance, validation and verification, and contract manufacture and outsourcing. Repeals the 2014 version.
• Medical Device Unique Identification Database Unique identification system for medical devices enabling tracking and traceability, with database functions opened to pilot enterprises for applying related data.
• Cosmetics Electronic Label System Digital label system using QR codes for cosmetics products including toothpaste, allowing consumers to access Chinese label information via smartphone scanning under the 2025 pilot program requirements.
• Information Sharing Procedure Between Regulatory Agencies Framework establishing principles and working procedures for sharing classified regulatory information between NMPA and other domestic and international regulatory agencies, with protocols for public and non-public information sharing.
• AI and Drug Regulation Framework Policy document establishing framework for integrating artificial intelligence into drug regulatory processes and regulatory technology, issued as Opinions on Integrated Development of AI and Drug Regulation.
• NMPA Public Database Public regulatory database providing access to drug approvals, medical device registrations, cosmetics filings, and other regulatory information under NMPA jurisdiction.
• NMPA Newsletter Periodic publication covering regulatory updates, policy interpretations, and industry developments, including Volume I 2026, Volume VI-V 2025, and Special Issue for Cosmetics, available as PDF downloads.
• Worldwide Pharmacopoeia Reference Reference resource providing access to pharmacopoeia standards from various countries, maintained by the Chinese Pharmacopoeia Commission as the official quality standards for drug regulation in China.
• Policies Interpretation Official guidance documents explaining regulatory policies, reforms, and implementation requirements for drugs, medical devices, and cosmetics, published on the NMPA website.
• Popular Science Resources Educational content for public understanding of pharmaceutical regulation, drug safety, and health topics, including articles published on the NMPA website such as the Warmth in Prescriptions series.

Quantifiable outcome

• Achieved 300th innovative medical device approval milestone
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature2 records

Partnerships

Twelve partnerships are on record, tiered core and major.

• World Health Organization (WHO)coreStrategic or Co-development PartnerNMPA collaborates with WHO on vaccine regulatory assessment, international pharmacopoeia standards, and participates in WHO's certification scheme for pharmaceutical products moving in international commerce. WHO pre-certification allows exemptions from on-site inspections for export certificates.
• Medicines Patent Pool (MPP)coreStrategic or Co-development PartnerMPP has signed agreements with Chinese regulatory authorities to facilitate access to medicines. NMPA provides streamlined export certificate processes for products with MPP authorization.
• International Council for Harmonisation (ICH)coreStrategic or Co-development PartnerNMPA has adopted ICH guidelines including safety guidelines (S-series), efficacy guidelines (E-series), and quality guidelines (Q-series) to align Chinese regulatory standards with international requirements.
• Pharmaceutical Inspection Co-operation Scheme (PIC/S)coreStrategic or Co-development PartnerNMPA is pursuing PIC/S membership to harmonize pharmaceutical inspection standards and enable mutual recognition of GMP inspections with international regulatory authorities.
• European Directorate for Quality of Medicines & Healthcare (EDQM)majorStrategic or Co-development PartnerNMPA cooperates with EDQM for GMP inspection recognition. Manufacturers that have passed GMP inspections by EDQM may be exempted from on-site inspections when applying for Written Confirmations for Active Substances Exported to the EU.
• National Institutes for Food and Drug Control (NIFDC)coreTechnology or IntegrationAffiliated institution of NMPA responsible for testing and control of food and drug products, providing technical support for regulatory decisions.
• Chinese Pharmacopoeia CommissioncoreTechnology or IntegrationDevelops and maintains pharmacopoeia standards for China, providing the official quality standards used in drug regulation and approval.
• Center for Drug Evaluation of NMPAcoreTechnology or IntegrationAffiliated institution responsible for technical review and evaluation of drug registration applications, including innovative drugs, generics, and imported pharmaceuticals.
• Center for Medical Device Evaluation of NMPAcoreTechnology or IntegrationAffiliated institution responsible for technical review of medical device registration applications and development of technical review guidelines.
• Center for Food and Drug Inspection of NMPAcoreTechnology or IntegrationAffiliated institution conducting quality inspections and laboratory testing for drugs and medical devices under NMPA oversight.
• Danish Medicines Agency / Novo NordiskmajorStrategic or Co-development PartnerDeputy Commissioner Yang Sheng met with Danish ambassador and Novo Nordisk chairman in June 2026 to discuss regulatory cooperation and pharmaceutical trade.
• Australian Therapeutic Goods AdministrationmajorStrategic or Co-development PartnerDeputy Commissioner Yang Sheng met with Australian ambassador to China to discuss regulatory cooperation and bilateral relations.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Health Canada: Canada's federal health regulator covering drugs, medical devices, and consumer health products. Comparable regulatory scope and structure to NMPA, with shared ICH membership.
• Pharmaceuticals and Medical Devices Agency (PMDA): Japan's regulatory agency working with MHLW on drug and medical device approvals. Comparable to NMPA in scientific review, GMP inspection, and post-market safety functions, and a key ICH counterpart.
• U.S. Food and Drug Administration (FDA): The U.S. federal regulatory authority for drugs, medical devices, cosmetics, and related products. It is the most direct functional counterpart to NMPA, performing the same core mandate of pre-market approval, GMP inspection, and post-market surveillance across comparable product categories.
• European Medicines Agency (EMA): The EU's central regulatory authority for medicinal products, with a comparable mandate on drug evaluation, scientific guideline setting, and coordination with national competent authorities — directly comparable to NMPA's drug and biologics oversight functions.
• Medicines and Healthcare products Regulatory Agency (MHRA): The UK's regulator for medicines, medical devices, and blood components. Shares NMPA's broad product scope (drugs + devices) and post-Brexit independent regulatory authority posture.
• Therapeutic Goods Administration (TGA, Australia): Australia's regulatory authority for therapeutic goods including medicines, medical devices, and cosmetics. NMPA already has direct bilateral engagement with the TGA, confirming functional comparability.
• Brazilian Health Regulatory Agency (ANVISA): Brazil's federal regulator for drugs, medical devices, cosmetics, and health products. Comparable in scope and emerging-market regulatory authority posture to NMPA.
• Ministry of Food and Drug Safety (MFDS, South Korea): South Korea's national regulator for food, drugs, medical devices, and cosmetics. Closely comparable in scope to NMPA and a regional peer in Asian pharmaceutical regulation.

Broad incumbents

• European Directorate for the Quality of Medicines & HealthCare (EDQM): A Council of Europe directorate overseeing pharmaceutical quality standards, including the European Pharmacopoeia and GMP inspection certification. NMPA already cooperates with EDQM for Written Confirmations for Active Substances Exported to the EU, making it a key reference peer.
• World Health Organization (WHO): The UN's global health authority that sets international pharmaceutical standards and maintains the Certification Scheme for pharmaceutical products in international commerce. NMPA is a WHO partner for vaccine NRA assessment and product certification, making WHO a top-tier regulatory peer.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nmpa-gov

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Medical Products Administration